Stocks and Investing
Stocks and Investing
Wed, April 12, 2017
[ 07:45 AM ] - United States, WOPRAI
[ 07:45 AM ] - United States, WOPRAI
[ 07:45 AM ] - United States, WOPRAI
[ 07:45 AM ] - United States, WOPRAI
[ 07:45 AM ] - United States, WOPRAI
[ 04:45 AM ] - United States, WOPRAI
[ 01:45 AM ] - United States, WOPRAI
[ 01:45 AM ] - United States, WOPRAI
[ 01:45 AM ] - United States, WOPRAI
[ 01:45 AM ] - United States, WOPRAI
[ 01:45 AM ] - United States, WOPRAI
[ 01:45 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
Kevin DeGeeter Initiated (CDTX) at Strong Buy and Held Target at $225 on, Apr 12th, 2017
Kevin DeGeeter of Ladenburg Thalmann, Initiated "Cidara Therapeutics, Inc." (CDTX) at Strong Buy and Held Target at $225 on, Apr 12th, 2017.
Kevin has made no other calls on CDTX in the last 4 months.
There are 3 other peers that have a rating on CDTX. Out of the 3 peers that are also analyzing CDTX, 1 agrees with Kevin's Rating of Hold. Following is the relevant analyst calls for the last 4 months
- Stephen Brozak of "WBB Securities" Upgraded from Strong Sell to Hold on, Wednesday, February 22nd, 2017
These are the ratings of the 2 analyists that currently disagree with Kevin
- Paul Matteis of "Leerink Swann" Initiated at Buy and Held Target at $340 on, Wednesday, December 21st, 2016
- Ed Arce of "HC Wainwright & Co." Initiated at Strong Buy and Held Target at $500 on, Monday, December 19th, 2016
Contributing Sources